Ten-Year Drugs Strategy
Debate between Crispin Blunt and Kit Malthouse(2 years, 11 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Kit Malthouse
As I say, I think there is a big difference with this plan, which is that on the supply side we are very much coming at this from an economic point of view. We have done an enormous amount of work to examine the nature of the business. We are not necessarily looking at the individuals involved, who very often are replaced if they are arrested—sometimes within hours—but fundamentally at the structure of the business, and interfering with it in a way that means it does not reoccur, using the method of distribution and communication against the business to make sure that we stamp it out. We are showing success across the country, particularly on county lines.
On drug consumption rooms, as I say, we remain open to evidence. We are looking at the evidence that has been presented by the Scottish Government, and we will respond to the Minister there shortly. However, as I say, even if that evidence was compelling—I am not convinced that it is at the moment—there are legislative obstacles that mean that we have no option for the moment but to focus on health investment and making sure that we ramp up treatment and rehabilitation, which we have seen have effect across the world.
Crispin Blunt (Reigate) (Con)
I welcome the commitment in the strategy to building a world-leading evidence base, and the funding of it, with a cross-Government innovation fund to test and learn. Given our desire to become world leaders in this space, will the Minister confirm that that evidence will include international examples and evidence?
Kit Malthouse
I am more than happy to confirm that we will look anywhere in the world where there are good ideas that are having impact and effect, but the evidence has to be properly evaluated, properly peer reviewed and scientifically proven, because we are dealing with people’s lives here. Across the world, we have seen unintended consequences from measures taken on narcotics, which we do not want to repeat. I know that my hon. Friend has done a lot of work in this area and that he is very well informed. I hope that, over the months and years to come, we can communicate regularly on this issue.
Point of Order
Debate between Crispin Blunt and Kit Malthouse(3 years, 1 month ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Crispin Blunt (Reigate) (Con)
On a point of order, Madam Deputy Speaker. On Monday, in answer to my supplementary question during Home Office questions, I believe—I have obtained guidance on the law from a senior lawyer—that the Minister for Crime and Policing most inadvertently misled the House, and I humbly invite him to take this early opportunity to correct the record. The Minister stated that the process for the rescheduling of compounds is that approval is given for a medicine by the Medicines and Healthcare products Regulatory Agency, and advice is then taken from the Advisory Council on the Misuse of Drugs about the rescheduling, as happened with Epidyolex. Nothing in the legislation requires MHRA authorisation for a compound drug to be moved to schedule 2 to 5 under the Misuse of Drugs Regulations 2001.
The effect of the Minister’s statement means that in practice, compounds will largely not be researched to become medicines. That would require market authorisation as, under the apparent new policy, which has so far never been presented to the House, compounds can never escape the rigours and expense of schedule 1. For British scientists that is a particular barrier to the exciting science around the psychedelic class of drugs that is now more easily developed and researched in North America than it is in the UK, where the science began. For those British scientists denied the opportunity to do that research, due to the costs imposed by the scheduling, it is a constant frustration that there is no recent scientific basis to support the scheduling in the first place.
The Minister’s statement was contradictory not only in logic, but also given recent precedent because—ironically, on the basis of the example given by the Minister—market authorisation for Epidyolex was granted two years after cannabis-based medicines and medicinal products as a whole were placed in schedule 2, precisely to facilitate the prescription of non-MHRA approved special medicines.
Oral Answers to Questions
Debate between Crispin Blunt and Kit Malthouse(3 years, 1 month ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Crispin Blunt (Reigate) (Con)
The Minister for Crime and Policing (Kit Malthouse)
We currently have no plans to reschedule psilocybin to schedule 2 of the Misuse of Drugs Regulations. The Advisory Council on the Misuse of Drugs has recently published stage 1 of its advice on reducing barriers to research on controlled drugs. We will consider the advice, including its implications for psilocybin, carefully before responding.
Crispin Blunt
Does my right hon. Friend understand the emerging potential of the psychedelic class of drugs, with psilocybin to the fore, to treat depression, trauma and addiction? Some of this science was emerging in the 1960s, before our current drugs laws closed it down. In 2019, 90,503 of our fellow citizens were driven to suicide by their depression or trauma, or their rock-bottom in addiction has been death. If there is any scale of potential for these drugs, and it appears that there is, any further delay in getting the science and research going is not defensible—in fact, it is a morally disgraceful abrogation of our duty to the public good.
Kit Malthouse
As a founder of the all-party group on life sciences, I am well aware of the potential of any number of compounds to assist us in the constant battle against mental and physical illness, and of the need for this country to lead in research that might alleviate the problem, not just here, but in the rest of the world. My hon. Friend will know that we reschedule particular compounds where medicines are approved on the advice of the Medicines and Healthcare products Regulatory Agency and of the ACMD. He will know that, for example, in June last year we placed Epidyolex, a cannabis-based medicine used to treat certain forms of epilepsy, in schedule 5 to the Misuse of Drugs Regulations, following exactly that sort of advice. There are ongoing trials and research studies into psilocybin taking place in the UK; a medicine has yet to be licensed by the MHRA, but if and when one is, we will consider rescheduling.